BioCryst Pharmaceuticals, Inc. (BCRX)
10.10
-0.07
(-0.69%)
USD |
NASDAQ |
Sep 03, 16:00
10.10
0.00 (0.00%)
After-Hours: 20:00
BioCryst Pharmaceuticals Research and Development Expense (Annual) : 164.74M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 164.74M |
| December 31, 2024 | 173.39M |
| December 31, 2023 | 214.91M |
| December 31, 2022 | 251.86M |
| December 31, 2021 | 208.03M |
| December 31, 2020 | 122.96M |
| December 31, 2019 | 107.07M |
| December 31, 2018 | 84.89M |
| December 31, 2017 | 66.96M |
| December 31, 2016 | 61.01M |
| December 31, 2015 | 72.76M |
| December 31, 2014 | 51.80M |
| December 31, 2013 | 37.73M |
| December 31, 2012 | 51.46M |
| December 31, 2011 | 56.90M |
| December 31, 2010 | 82.47M |
| Date | Value |
|---|---|
| December 31, 2009 | 72.30M |
| December 31, 2008 | 73.33M |
| December 31, 2007 | 94.05M |
| December 31, 2006 | 47.08M |
| December 31, 2005 | 23.64M |
| December 31, 2004 | 18.87M |
| December 31, 2003 | 11.52M |
| December 31, 2002 | 15.47M |
| December 31, 2001 | 13.09M |
| December 31, 2000 | 9.590M |
| December 31, 1999 | 7.683M |
| December 31, 1998 | 9.291M |
| December 31, 1997 | 10.58M |
| December 31, 1996 | 7.586M |
| December 31, 1995 | 7.107M |
| December 31, 1994 | 5.552M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Amgen, Inc. | 6.974B |
| Vertex Pharmaceuticals, Inc. | 3.754B |
| Agenus, Inc. | 79.34M |
| Anika Therapeutics, Inc. | 25.77M |
| Imunon, Inc. | 7.781M |